"/>

3分pk10-(中国)360百科

New immunotherapy approach brings promises for some cancer patients

Source: Xinhua    2018-06-05 02:33:03

WASHINGTON, June 4 (Xinhua) -- American researchers at the National Cancer Institute (NCI) have developed a novel approach to immunotherapy that leads to the complete regression of breast cancer in a patient who was unresponsive to all other treatments.

The patient received the treatment in a clinical trial, according to the findings published on Monday in the journal Nature Medicine.

"We've developed a high-throughput method to identify mutations present in a cancer that are recognized by the immune system," said Steven A. Rosenberg, chief of the Surgery Branch at NCI's Center for Cancer Research (CCR).

"This research is experimental right now. But because this new approach to immunotherapy is dependent on mutations, not on cancer type, it is in a sense a blueprint we can use for the treatment of many types of cancer," said Rosenberg.

The new immunotherapy approach is a modified form of adoptive cell transfer (ACT). ACT has been effective in treating melanoma, which has high levels of somatic, or acquired, mutations.

However, ACT has been usually less effective with some common epithelial cancers, or cancers that start in the lining of organs that have lower levels of mutations, such as stomach, esophageal, ovarian, and breast cancers.

In an ongoing phase 2 clinical trial, the investigators are developing a form of ACT that uses tumor-infiltrating lymphocytes (TILs) that specifically target tumor cell mutations to see if they can shrink tumors in patients with these common epithelial cancers.

As with other forms of ACT, the selected TILs are grown to large numbers in the laboratory and are then infused back into the patient to create a stronger immune response against the tumor.

A patient with metastatic breast cancer came to the trial after receiving multiple treatments, including several chemotherapy and hormonal treatments, which had not stopped her cancer from progressing.

To treat her, the researchers sequenced DNA and RNA from one of her tumors, as well as normal tissue to see which mutations were unique to her cancer, and identified 62 different mutations in her tumor cells.

The researchers then tested different TILs from the patient to find those that recognized one or more of these mutated proteins. Then TILs recognized four of the mutant proteins, and the TILs were expanded and infused back into the patient.

She was also given the checkpoint inhibitor pembrolizumab to prevent the possible inactivation of the infused T-cells by factors in the tumor microenvironment.

After the treatment, all of this patient's cancer disappeared and has not returned more than 22 months later.

"If confirmed in a larger study, it promises to further extend the reach of this T-cell therapy to a broader spectrum of cancers," said Tom Misteli, director of CCR at NCI.

Investigators have seen similar results using mutation-targeted TIL treatment for patients in the same trial with other epithelial cancers, including liver cancer and colorectal cancer.

Editor: yan
Related News
Xinhuanet

New immunotherapy approach brings promises for some cancer patients

Source: Xinhua 2018-06-05 02:33:03

WASHINGTON, June 4 (Xinhua) -- American researchers at the National Cancer Institute (NCI) have developed a novel approach to immunotherapy that leads to the complete regression of breast cancer in a patient who was unresponsive to all other treatments.

The patient received the treatment in a clinical trial, according to the findings published on Monday in the journal Nature Medicine.

"We've developed a high-throughput method to identify mutations present in a cancer that are recognized by the immune system," said Steven A. Rosenberg, chief of the Surgery Branch at NCI's Center for Cancer Research (CCR).

"This research is experimental right now. But because this new approach to immunotherapy is dependent on mutations, not on cancer type, it is in a sense a blueprint we can use for the treatment of many types of cancer," said Rosenberg.

The new immunotherapy approach is a modified form of adoptive cell transfer (ACT). ACT has been effective in treating melanoma, which has high levels of somatic, or acquired, mutations.

However, ACT has been usually less effective with some common epithelial cancers, or cancers that start in the lining of organs that have lower levels of mutations, such as stomach, esophageal, ovarian, and breast cancers.

In an ongoing phase 2 clinical trial, the investigators are developing a form of ACT that uses tumor-infiltrating lymphocytes (TILs) that specifically target tumor cell mutations to see if they can shrink tumors in patients with these common epithelial cancers.

As with other forms of ACT, the selected TILs are grown to large numbers in the laboratory and are then infused back into the patient to create a stronger immune response against the tumor.

A patient with metastatic breast cancer came to the trial after receiving multiple treatments, including several chemotherapy and hormonal treatments, which had not stopped her cancer from progressing.

To treat her, the researchers sequenced DNA and RNA from one of her tumors, as well as normal tissue to see which mutations were unique to her cancer, and identified 62 different mutations in her tumor cells.

The researchers then tested different TILs from the patient to find those that recognized one or more of these mutated proteins. Then TILs recognized four of the mutant proteins, and the TILs were expanded and infused back into the patient.

She was also given the checkpoint inhibitor pembrolizumab to prevent the possible inactivation of the infused T-cells by factors in the tumor microenvironment.

After the treatment, all of this patient's cancer disappeared and has not returned more than 22 months later.

"If confirmed in a larger study, it promises to further extend the reach of this T-cell therapy to a broader spectrum of cancers," said Tom Misteli, director of CCR at NCI.

Investigators have seen similar results using mutation-targeted TIL treatment for patients in the same trial with other epithelial cancers, including liver cancer and colorectal cancer.

[Editor: huaxia]
010020070750000000000000011105521372300571
快3彩票购彩平台 大发彩票welcome 彩神 5分pk10 乐彩彩票 快三网站 大众购彩 一分11选5 极速快3 五分快乐十分 大发购彩中心 乐发lll 大发welcome 大发系列平台 东方彩票 五五世纪平台 凤凰快3 乐发IV彩票购彩中心 彩88 凤凰彩票官方网站 5分pk10 五五世纪 山西快3 55世纪购彩平台 乐发lx Welcome彩神 乐发3彩票APP 购彩中心 55世纪-购彩大厅 大发云app 星辰阁彩票购彩大厅 彩神v 大发彩票购彩平台 5分快3 快三彩票购彩平台 大發3分快3 快3平台 乐彩彩票 大发彩票快乐8 乐发IV welcome手机购彩 大众购彩 天天中平台 快盈IV500 幸运快三 买大小平台赚钱 1分快3 彩神彩票购彩平台 大发pk10 彩信平台 三分11选5 快3购彩中心 乐发ll下载app 彩神Welcome登录入口 乐发 采彡神争霸 快盈iv 神彩v8 55世纪官网 大发彩票www官方 凤凰彩票 10分快三 快三彩票官方网站 五分飞艇 乐发彩票官方网站 乐发Vll 大发快乐8官网 乐发app 大发彩票welcome 幸运5分彩 百姓快3 百度彩票 彩神网 大发彩票 3分快三 快3彩票 一分11选5 极速快3 五分快乐十分 大发购彩中心 乐发lll 大发welcome 大发系列平台 东方彩票 五五世纪平台 凤凰快3 乐发IV彩票购彩中心 彩88 凤凰彩票官方网站 5分pk10 55世纪 重庆快3 55世纪官方网站 乐发VI 彩神 乐发Ⅲ welcome大发彩票 大发购彩大厅welcome 百姓快三 名发app PK彩票 大发彩票购彩平台 5分快3 快三彩票购彩平台 大發3分快3 快3平台 乐彩彩票 大发彩票快乐8 乐发IV welcome手机购彩 五分快三 10元投资彩票赚钱平台 鼎发彩票 彩神iv争霸 网信快3 一分快3 凤凰彩票app下载 3分pk10 乐彩 湖南快3 快3购彩平台 乐发lv 彩神Welcome入口 乐发1 彩神8 百姓彩票welcome 一分三可空降可约app下载 彩神ix 彩票宝 大发彩票app下载 10分快3 快3彩神官方网站 四川快3 乐发彩票购彩平台 乐发彩票ll 大发快乐8官方网站 乐发app下载 welcome凤凰彩票 万乐彩 在线快3 百度彩票 彩神网 大发彩票 3分快三 快3彩票 一分11选5 极速快3 五分快乐十分 大发购彩中心 乐发lll 彩神welcome 乐发网投平台 网信彩票 优彩彩票 彩神8v 网信快三 乐乐彩 凤凰彩票购彩平台 10分pk10 55世纪 重庆快3 55世纪官方网站 乐发VI 彩神 乐发Ⅲ welcome大发彩票 大发购彩大厅welcome 百姓快三 名发app PK彩票 大发彩票购彩平台 5分快3 快三彩票购彩平台 大發3分快3 快3平台 分分快3 大发快乐8 乐发ll welcome购彩中心 五分快三 10元投资彩票赚钱平台 鼎发彩票 彩神iv争霸 网信快3 一分快3 凤凰彩票app下载 3分pk10 乐彩 湖南快3 55世纪购彩平台 乐发lx Welcome彩神 乐发3彩票APP 购彩中心 55世纪-购彩大厅 大发云app 星辰阁彩票购彩大厅 彩神v 大发彩票官方网站 五分快3 快3彩票购彩平台 三分PK10 乐发彩票 乐发国际 大发快乐8购彩平台 乐发III 手机购彩 一分快3平台 彩神v8 快三网站 天天彩票 快三平台 1分快三 彩神彩票官方网站 大发三分快3 极速快三 三分PC蛋蛋 彩神购彩中心 乐发lll下载 彩神welcome 乐发网投平台 网信彩票 优彩彩票 彩神8v 网信快三 乐乐彩 凤凰彩票购彩平台 10分pk10 快三彩票官方网站 五分飞艇 乐发彩票官方网站 乐发Vll 大发快乐8官网 乐发app 大发彩票welcome 幸运5分彩 百姓快3 vip彩票购彩大厅 直播快三 彩神彩票 3分快3 快三彩票 大發5分快3 极速快3购彩平台 分分快3 大发快乐8 乐发ll welcome购彩中心 五分快三 10元投资彩票赚钱平台 鼎发彩票 彩神iv争霸 网信快3 一分快3 凤凰彩票app下载 3分pk10 乐彩 湖南快3 快3购彩平台 乐发lv 彩神Welcome入口 乐发3彩票APP 购彩中心 55世纪-购彩大厅 大发云app 星辰阁彩票购彩大厅 彩神v 大发彩票购彩平台 5分快3 快三彩票购彩平台 大發3分快3 快3平台 乐彩彩票 大发彩票快乐8 乐发IV welcome手机购彩 大众购彩 天天中平台 快盈IV500 幸运快三 买大小平台赚钱 1分快3 彩神彩票购彩平台 大发pk10 彩信平台 三分11选5 快3购彩中心 乐发ll下载app 彩神Welcome登录入口 乐发 采彡神争霸 快盈iv 神彩v8 55世纪官网 大发彩票www官方 凤凰彩票 10分快三 快三彩票官方网站 五分飞艇 乐发彩票官方网站 乐发Vll 大发快乐8官网 乐发app 大发彩票welcome 幸运5分彩 百姓快3 百度彩票 彩神网 大发彩票 3分快三 快3彩票 一分11选5 极速快3 五分快乐十分 大发购彩中心 乐发lll 大发welcome 大发系列平台 东方彩票 五五世纪平台 凤凰快3 乐发IV彩票购彩中心 彩88 凤凰彩票官方网站 5分pk10 五五世纪 山西快3 55世纪购彩平台 乐发lx Welcome彩神 乐发3彩票APP 购彩中心 55世纪-购彩大厅 大发云app 星辰阁彩票购彩大厅 彩神v 大发彩票官方网站 五分快3 快3彩票购彩平台 三分PK10 乐发彩票 乐发国际 大发快乐8购彩平台 乐发III 手机购彩 一分快3平台 10元投资彩票赚钱平台 鼎发彩票 彩神iv争霸 网信快3 一分快3 凤凰彩票app下载 3分pk10 乐彩 湖南快3 快3购彩平台 乐发lv 彩神Welcome入口 乐发1 彩神8 百姓彩票welcome 一分三可空降可约app下载 彩神ix 彩票宝 大发彩票app下载 10分快3 快3彩神官方网站 四川快3 乐发彩票购彩平台 乐发彩票ll 大发快乐8官方网站 乐发app下载 welcome凤凰彩票 万乐彩 在线快3 百度彩票 彩神网 大发彩票 3分快三 快3彩票 一分11选5 极速快3 五分快乐十分 大发购彩中心 乐发lll 彩神welcome 乐发网投平台 网信彩票 优彩彩票 彩神8v 网信快三 乐乐彩 凤凰彩票购彩平台 10分pk10 55世纪 重庆快3 55世纪官方网站 乐发VI 彩神 乐发Ⅲ welcome大发彩票 大发购彩大厅welcome 百姓快三 名发app PK彩票 大发彩票购彩平台 5分快3 快三彩票购彩平台 大發3分快3 快3平台 乐彩彩票 大发彩票快乐8 乐发IV welcome手机购彩 大众购彩 天天中平台 快盈IV500 幸运快三 买大小平台赚钱 1分快3 彩神彩票购彩平台 大发pk10 彩信平台 三分11选5 快3购彩平台 乐发lv 彩神Welcome入口 乐发1 彩神8 百姓彩票welcome 一分三可空降可约app下载 星辰阁彩票购彩大厅 彩神v 大发彩票官方网站 五分快3 快3彩票购彩平台 三分PK10 乐发彩票 乐发国际 大发快乐8购彩平台 乐发III 手机购彩 一分快3平台 彩神v8 快三网站 天天彩票 快三平台 1分快三 彩神彩票官方网站 大发三分快3 极速快三 三分PC蛋蛋 彩神购彩中心 乐发lll下载 彩神welcome 乐发网投平台 网信彩票